No Detail Found!

Role of PSA Kinetics in Hormone-refractory Prostate Cancer

Author(s)
Volkan Sabur Department of Urology, Erciyes Kartal Hospital,Kayseri,Turkey
Ibrahim Untan Department of Urology, Ahi Evran University, Training and Research Hospital,Kirsehir,Turkey
Atila Tatlisen Department of Urology, Erciyes University, Faculty of Medicine,Kayseri,Turkey
Abstract
Objective: To demonstrate the predictive e ect of PSA derivatives and time markers that is prostate-speci c antigen (PSA) doubling time (PSADT) and PSA velocity (PSAV) on survival in men with hormone-refractory prostate cancer (HRPCa). Study Design: Descriptive, analytical study. Place and Duration of Study: Department of Urology, Erciyes University, Faculty of Medicine, Kayseri, Turkey, between 2012 and 2020. Methodology: One hundred patients, who were treated with prostate cancer, were subjected. The PSA values were noted, nadir PSA values were detected, times to nadir PSA, HRPCa, and follow-up times were recorded. PSADT and PSAV were calculated. The relationships between the groups were analyzed. Kaplan-Meier curves were used to estimate overall survival between the groups. Results: The patients were grouped according to the mean PSADT, median PSAV, median nadir PSA, and mean time to HRPCA. The survival of those with high PSADT, low PSAV and low nadir PSA were found to be signi cantly longer (p=0.006<,0p.001, p<0.001). High PSAV was also associated with signi cantly increased PSA, nadir PSA and death (p<p0=.000.14,7, and p<0.001, p=0.52, respectively). The survival of those with a longer time to HPRCa was found to be signi cantly longer (p<0.001). There was no statistically signi cant di erence in terms of survival between patients who received chemotherapy after HRPCa and those who did not (p=0.477). PSAV (p=0.007 HR: 1.004 95% CI: 1.001 1.007), bone metastasis at diagnosis (p=0.001 HR: 0.357 95% CI: 0.197 0.645) and time to HRPCa development (p=0.001 HR: 0.936 95% CI: 0.900 0.974) were signi cantly e ective to the survival. Conclusion: PSADT, PSAV, and nadir PSA serve as independent prognostic markers for survival in patients with HRPCa. These three PSA derived calculation products, with the help of other parameters, could work as prognostic factors, and help clinicians predict survival in men with HRPCa.
Publication Details
Page(s) 673-678
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 6, Year: 2021

Request the full text from PASTIC

Keywords
Survival, Prognostic factors, Hormone-refractory prostate cancer, PSA kinetics
0

Citations

0

Downloads

38

Views